$2.01
+0.07 (+3.61%)
Open$1.96
Previous Close$1.94
Day High$2.03
Day Low$1.93
52W High$4.34
52W Low$1.41
Volume—
Avg Volume938.2K
Market Cap72.69M
P/E Ratio—
EPS$-0.65
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,395.0% upside
Current
$2.01
$2.01
Target
$30.05
$30.05
$22.12
$30.05 avg
$38.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.43M | 10.74M | 10.31M |
| Net Income | -2,402,162 | -1,945,366 | -2,138,218 |
| Profit Margin | -21.0% | -18.1% | -20.7% |
| EBITDA | -3,961,862 | -3,629,854 | -3,514,676 |
| Free Cash Flow | -2,281,552 | -2,429,555 | -1,597,015 |
| Rev Growth | +22.4% | -6.0% | +21.1% |
| Debt/Equity | 1.10 | 1.30 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |